康缘药业(600557.SH)前三季度净利润2亿元，同比下降35.63%

Group 1 - The core viewpoint of the article is that Kangyuan Pharmaceutical (600557.SH) reported a significant decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Group 2 - The total operating revenue for the first three quarters reached 2.343 billion yuan, representing a year-on-year decrease of 24.59% [1] - The net profit attributable to shareholders of the parent company was 200 million yuan, down 35.63% year-on-year [1] - The basic earnings per share were reported at 0.35 yuan [1]